THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, has named Dawn McGuire, M.D., to its Clinical Advisory Board (CAB) for multiple sclerosis (MS). Dr. McGuire, a board- certified physician in neurology and psychiatry, is the chief medical officer of Pepgen Corporation, a privately held company based in Alameda, Calif. seeking to develop and commercialize products for autoimmune and viral disorders. Prior to joining Pepgen in 2006, Dr. McGuire served from 2004 to 2006 as chief medical officer of Avigen, a biotechnology company focused on gene therapy in neurological disorders. While serving as vice president of clinical research at Elan Pharmaceuticals, she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of MS.
